HC Wainwright Has Optimistic Outlook of Absci Q3 Earnings

Absci Corporation (NASDAQ:ABSI) – Investment analysts at HC Wainwright increased their Q3 2026 EPS estimates for shares of Absci in a research report issued to clients and investors on Monday, May 11th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of ($0.22) for the quarter, up from their previous estimate of ($0.23). The consensus estimate for Absci’s current full-year earnings is ($0.83) per share. HC Wainwright also issued estimates for Absci’s Q4 2026 earnings at ($0.22) EPS, FY2026 earnings at ($0.84) EPS, Q1 2027 earnings at ($0.12) EPS, Q2 2027 earnings at ($0.16) EPS, Q3 2027 earnings at $0.12 EPS, Q4 2027 earnings at ($0.18) EPS, FY2028 earnings at $0.11 EPS and FY2029 earnings at $0.09 EPS.

Absci (NASDAQ:ABSI) last released its earnings results on Thursday, May 7th. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.01. Absci had a negative net margin of 6,450.76% and a negative return on equity of 66.32%. The company had revenue of $0.22 million for the quarter, compared to analyst estimates of $1.39 million.

Several other equities analysts have also commented on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $7.00 target price on shares of Absci in a report on Wednesday, March 25th. Truist Financial increased their target price on shares of Absci from $9.00 to $11.00 and gave the company a “buy” rating in a report on Friday, May 8th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Absci in a report on Monday, April 20th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $7.58.

Absci Stock Performance

ABSI stock opened at $5.36 on Wednesday. Absci has a 52 week low of $2.24 and a 52 week high of $6.72. The firm’s fifty day moving average is $3.47 and its 200 day moving average is $3.34. The firm has a market cap of $835.65 million, a P/E ratio of -6.46 and a beta of 2.36.

Institutional Investors Weigh In On Absci

Large investors have recently added to or reduced their stakes in the company. ARK Investment Management LLC grew its holdings in Absci by 21.1% in the 3rd quarter. ARK Investment Management LLC now owns 12,162,773 shares of the company’s stock worth $36,975,000 after acquiring an additional 2,116,845 shares during the last quarter. Heights Capital Management Inc. bought a new stake in Absci in the 3rd quarter worth $6,081,000. BNP Paribas Financial Markets boosted its stake in shares of Absci by 91.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 11,287 shares of the company’s stock valued at $29,000 after purchasing an additional 5,385 shares in the last quarter. Quarry LP bought a new stake in shares of Absci during the 3rd quarter valued at about $26,000. Finally, Principal Financial Group Inc. bought a new stake in shares of Absci during the 1st quarter valued at about $31,000. Institutional investors own 52.05% of the company’s stock.

Insider Transactions at Absci

In other news, insider Andreas Busch purchased 100,000 shares of the business’s stock in a transaction on Thursday, March 12th. The shares were acquired at an average price of $2.29 per share, with a total value of $229,000.00. Following the acquisition, the insider directly owned 421,446 shares in the company, valued at approximately $965,111.34. The trade was a 31.11% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 10.49% of the stock is currently owned by company insiders.

Absci News Roundup

Here are the key news stories impacting Absci this week:

• Positive Sentiment: HC Wainwright raised its longer-term earnings outlook for Absci, including higher FY2028 and FY2029 EPS estimates, suggesting improving profitability prospects over time. Absci analyst estimate updates
• Positive Sentiment: The firm also nudged up its FY2030 EPS estimate, reinforcing the view that Absci could generate meaningful earnings in the out-years if execution improves. Absci analyst estimate updates
• Neutral Sentiment: HC Wainwright also made modest revisions to near-term estimates, including slightly better Q3 2026 and Q4 2026 EPS forecasts, but the company is still expected to post losses through at least 2027. Absci analyst estimate updates
• Negative Sentiment: Even with the revised estimates, consensus expectations still point to a full-year loss, and Absci’s recent quarterly results showed very low revenue versus expectations, keeping pressure on the stock. Absci earnings results

Absci Company Profile

Absci Corporation (NASDAQ: ABSI) is a biotechnology company that applies machine learning, synthetic biology and automation to accelerate the discovery and development of protein-based therapeutics. The company’s Integrated Drug Creation® (IDC®) platform is designed to identify and produce novel antibody and enzyme candidates at speeds and scales that traditional biopharma discovery methods cannot match. Absci works with pharmaceutical and biotechnology partners to generate, screen and optimize protein molecules for a wide range of therapeutic applications.

The core of Absci’s offering is its end-to-end discovery engine, which combines proprietary algorithms, high-throughput laboratory automation and a deep learning framework.